Home | List of Topics | Children's Health | Newborn Care
Newborn screening tests look for serious developmental, genetic, and metabolic disorders so that important action can be taken during the critical time before symptoms develop.
In the United States, the individual states each regulate newborn screening, so the diseases screened for vary considerably. Most states require three to eight tests, but organizations such as the March of Dimes and the American College of Medical Genetics suggest more than two dozen additional tests.
The most thorough screening panel checks for about 40 disorders. All 50 states screen for congenital hypothyroidism, galactosemia, and phenylketonuria (PKU).
Infant screening tests; Neonatal screening tests
Blood tests: A health care professional will prick the baby’s heel to obtain a few drops of blood. The blood is sent to a lab for analysis.
Hearing test: An audiologist will place a tiny earpiece or microphone in the infant’s ear or stick electrodes on the baby’s head.
There is no preparation necessary for newborn screening tests. The tests are performed when the baby is between 24 hours and 7 days old, typically before the baby goes home from the hospital.
The baby will most likely cry when his or her heel is pricked to obtain the small blood sample. The hearing test should not cause the baby to feel pain, cry, or respond.
Screening tests do not diagnose illnesses. They identify which babies need additional testing to confirm or rule out illnesses. Good screening tests have a low false-negative rate (if the test is normal, the child should be healthy), but may have a high false-positive rate (as many affected children as possible should test positive, even if this means many healthy children also test positive).
If a disorder is diagnosed on follow-up testing, appropriate treatment can be started right away, before symptoms appear.
Screening tests are used to detect a number of disorders, including:
See also: APGAR test
Normal values for each screening test may vary depending on how the test is performed.
An abnormal result means that the child should have additional testing to confirm or rule out the condition.
Risks for the newborn heel prick blood sample include pain and possible bruising at the site where the blood was obtained.
Newborn testing is critical for the baby to receive treatment that may be life saving. However, not all disorders that can be detected by the screening tests can be treated.
Although states do not perform all screening tests, parents can have additional tests done by qualified laboratories at large medical centers. Private laboratories also offer newborn screening. Parents can find out about extra newborn screening tests from their physician or hospital where the baby will be born, as well as through organizations like the March of Dimes.
American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system--executive summary. Pediatrics. 2006 May;117(5 Pt 2):S296-307.
Graves JC, Miller KE, Sellers AD. Maternal serum triple analyte screening in pregnancy. Am Fam Physician. 2002 Mar 1;65(5):915-20.
Grosse SD, Boyle CA, Cordero JF. Newborn screening for cystic fibrosis: recommendations from the Centers for Disease Control and Prevention. Am Fam Physician. 2005 Apr 15;71(8):1482, 1487.
Bryant KG, Horns KM, Longo N, Schiefelbein J. A primer on newborn screening. Adv Neonatal Care. 2004 Oct;4(5):306-17.
Carreiro-Lewandowski E. Newborn screening: an overview. Clin Lab Sci. 2002 Fall;15(4):229-38.
Centers for Disease Control and Prevention. Newborn Screening for Cystic Fibrosis: Evaluation of Benefits and Risks and Recommendations for State Newborn Screening Programs. J Pediatr. 2005 Sep;147(3 Suppl):S1.
Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004 Oct 15;53(RR-13):1-36.
Review Date:9/6/2007
Reviewed By:Alan Greene, M.D., F.A.A.P., Department of Pediatrics, Stanford School of Medicine; Lucile Packard Children's Hospital; Chief Medical Officer, A.D.A.M., Inc., and Deirdre O’Reilly, M.D., M.P.H., Neonatologist, Division of Newborn Medicine, Children’s Hospital Boston and Instructor in Pediatrics, Harvard Medical School, Boston, Massachusetts.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The Agency for Health Care Administration (Agency) and this website do not claim the information on, or referred to by, this site is error free. This site may include links to websites of other government agencies or private groups. Our Agency and this website do not control such sites and are not responsible for their content. Reference to or links to any other group, product, service, or information does not mean our Agency or this website approves of that group, product, service, or information.
Additionally, while health information provided through this website may be a valuable resource for the public, it is not designed to offer medical advice. Talk with your doctor about medical care questions you may have.